# EDGAR Filing Document

**Accession Number:** 0001630627
**File Stem:** 0001193125-25-269556
**Filing Date:** 2025-11
**Character Count:** 130178
**Document Hash:** cec5779461736c997c071bc43c6410b4
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-269556.hdr.sgml**: 20251106

**ACCESSION NUMBER**: 0001193125-25-269556

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 54

**CONFORMED PERIOD OF REPORT**: 20250930

**FILED AS OF DATE**: 20251106

**DATE AS OF CHANGE**: 20251106

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** TREACE MEDICAL CONCEPTS, INC.
- **CENTRAL INDEX KEY:** 0001630627
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 471052611
- **STATE OF INCORPORATION:** FL
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40355
- **FILM NUMBER:** 251458471

**BUSINESS ADDRESS:**
- **STREET 1:** 100 PALMETTO PARK PLACE
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32081
- **BUSINESS PHONE:** (904) 373-5940

**MAIL ADDRESS:**
- **STREET 1:** 100 PALMETTO PARK PLACE
- **CITY:** PONTE VEDRA
- **STATE:** FL
- **ZIP:** 32081

?xml version='1.0' encoding='ASCII'? 10-Q

inno00."333

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form** 10-Q

**(Mark one)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended** **September 30,** 2025

**or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from___ to___**

**Commission file number:** 001-40355

Treace Medical Concepts, Inc.

*(Exact name of registrant as specified in its charter)*

Delaware 47-1052611 <br> *(State or other jurisdiction of incorporation or organization)* *(I.R.S. Employer Identification No.)*

100 Palmetto Park Place

Ponte Vedra**,** Florida 32081

*(Address of principal executive offices, including zip code)*

**(**904**)** 373-5940

*(Registrant's telephone number, including area code)*

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading symbol(s)** | **Name of each exchange on which registered** |
| Common stock, $0.001 par value | TMCI | The Nasdaq Global Select Market |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of October 31, 2025, 63,718,073 shares of the registrant's common stock, $0.001 par value per share, were outstanding.

------

**TREACE MEDICAL CONCEPTS, INC.** 

**FORM 10-Q FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025**

**Table of Contents**

[<u>Special Note Regarding Forward-Looking Statements</u>](#special_note_)<sub>1</sub>

**Part I: Financial Information**

---

| | | |
|:---|:---|:---|
| Item 1. | [<u>Condensed Financial Statements</u>](#item_1_financial_statements_unaudited) | 3 |
|  | [<u>Condensed Balance Sheets</u>](#condensed_balance_sheets) | 3 |
|  | [<u>Condensed Statements of Operations and Comprehensive Loss</u>](#condensed_statement_operations_comprehen) | 4 |
|  | [<u>Condensed Statements of Stockholders' Equity</u>](#condensed_statement_stockholders_equity_) | 5 |
|  | [<u>Condensed Statements of Cash Flows</u>](#condensed_statements_cash_flows) | 6 |
|  | [<u>Notes to Condensed Financial Statements</u>](#notes_to_condensed_consolidated) | 7 |
| Item 2. | [<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>](#item_2_managements_discussion_analysis_f) | 16 |
| Item 3. | [<u>Quantitative and Qualitative Disclosures About Market Risk</u>](#item_3_quantitative_qualitative_disclosu) | 26 |
| Item 4. | [<u>Controls and Procedures</u>](#item_4_controls_procedures) | 26 |

---

---

| | | |
|:---|:---|:---|
|  | **Part II: Other Information** |  |
| Item 1. | [<u>Legal Proceedings</u>](#item_1_legal_proceedings) | 27 |
| Item 1A. | [<u>Risk Factors</u>](#item_1a_risk_factors) | 27 |
| Item 2. | [<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>](#item_2_unregistered_sales_equity_securit) | 28 |
| Item 3. | [<u>Defaults Upon Senior Securities</u>](#item_3_defaults_upon_senior_securities) | 28 |
| Item 4. | [<u>Mine Safety Disclosures</u>](#item_4_mine_safety_disclosures) | 28 |
| Item 5. | [<u>Other Information</u>](#item_5_or_information) | 28 |
| Item 6. | [<u>Exhibits</u>](#item_6_exhibits) | 28 |
|  | [<u>Signatures</u>](#signatures) | 29 |

---

------

**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS** 

As used in this Quarterly Report on Form 10-Q ("Quarterly Report"), unless expressly indicated or the context otherwise requires, references to "Treace Medical Concepts," "we," "us," "our," or the "Company," refer to Treace Medical Concepts, Inc. This Quarterly Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as codified in Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "assume," "believe," "contemplate," "continue," "could," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "predict," "potential," "positioned," "seek," "should," "slated," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.

These forward-looking statements include, but are not limited to, statements about:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the expected use of our products by physicians;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the expected growth of our business and our organization and expected improvements in profitability, cash usage, and other financial results;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to increase market share and effectively respond to and mitigate the impact of challenges in the current market environment, including the extensive competition in our industry and new product introductions from other industry participants, including in both the Lapidus market and the minimally invasive osteotomy market;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to control and reduce expenses to help offset changes in revenue growth rates and other events;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our plans and expected timeline related to our products, or developing or acquiring new products, to address additional indications or otherwise, and the timing and extent that customers adopt and continue to use our products, including our flagship Lapiplasty<sup>®</sup> system which has higher average selling prices than our new osteotomy and great toe fusion systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to maintain sufficient balance sheet strength to continue executing on our strategic investments and growth initiatives for the foreseeable future;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•expected seasonality;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of inflationary pressures, interest rate changes, evolving or increased tariffs, changes in trade policy or global trade disruptions, protracted government shutdowns, business downturns, higher insurance deductibles and costs, consumer sentiment, and general economic conditions on the overall state of the economy, on patient behavior and demand for elective surgeries, on customers' and suppliers' operations, and on our business and results of operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expectations regarding government and third-party payor coverage and reimbursement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the economic success and viability of the hospitals, ambulatory surgery centers, surgeons, and stocking distributors that buy our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of sales to stocking distributors and other customers on product revenues in future periods, particularly if softening demand means that products already purchased by customers are used more slowly for future cases;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our estimates of our expenses, ongoing losses, future revenue, capital requirements and our need for, or ability to obtain, additional financing or refinance outstanding debt;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our expected uses of our existing cash, cash equivalents and marketable securities and the sufficiency of such resources to fund our planned operations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to retain and recruit key personnel and optimize our existing sales and marketing infrastructure;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain an adequate supply of materials and components for our products, some of which are single-source suppliers;

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain and maintain intellectual property protection for our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to protect and enforce our intellectual property, and the time and expense involved in monitoring unauthorized uses of our intellectual property, including in connection with the lawsuits we initiated in October 2024 and May 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to successfully defend against infringement of our intellectual property by third parties, including our competitors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact on our operations, business, supply chain, patient demand for elective surgeries, and hospital and surgeon availability as a result of natural or other disasters, including hurricanes, floods, tornadoes and other climate-related events, power loss, strikes or other events beyond our control;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to obtain, maintain and expand regulatory clearances for our products and any new products we develop or acquire;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our ability to expand our business in current and new geographic markets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our compliance with Nasdaq requirements and government laws, rules and regulations;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of geopolitical tensions and international conflicts on the economy and our business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of a bankruptcy filing by any of our customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our plans to conduct further clinical studies;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the outcome and expense of pending and threatened litigation, or legal proceedings, including a pending purported federal securities class action; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effect of any infectious disease outbreak and its impact or potential impact on our business or on the healthcare industry, particularly elective surgeries where our products are used.

We believe that it is important to communicate our future expectations to our investors. However, there may be events in the future that we are not able to accurately predict or control and that may cause our actual results to differ materially from the expectations we describe in our forward-looking statements. These forward-looking statements are based on management's current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management's beliefs and assumptions, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors many of which are beyond our control. As a result, any or all of our forward-looking statements in this Quarterly Report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those set forth in our Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission ("SEC"), and this Quarterly Report under "Risk Factors" and elsewhere in this Quarterly Report. Readers are urged to consider these factors carefully in evaluating the forward-looking statements.

These forward-looking statements speak only as of the date of this Quarterly Report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

You should read this Quarterly Report and the documents that we reference in this Quarterly Report and have filed with the SEC as exhibits to this Quarterly Report with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

------

**PART I–FINANCIAL INFORMATION**

**Item 1. Condensed Financial Statements.**

**TREACE MEDICAL CONCEPTS, INC.** 

**Condensed Balance Sheets** 

**(in thousands, except share and per share amounts)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| **Assets** |  |  |
| Current assets |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $7686 | $11350 |
| &nbsp;&nbsp;&nbsp;&nbsp;Marketable securities, short-term | 49730 | 64327 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net of allowance for credit losses of $1,505 and $1,326 as of September 30, 2025 and December 31, 2024, respectively | 32959 | 40803 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | 41424 | 39255 |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 6198 | 5667 |
| Total current assets | 137997 | 161402 |
| Property and equipment, net | 29970 | 25953 |
| Intangible assets, net of accumulated amortization of $2,138 and $1,425 as of September 30, 2025 and December 31, 2024, respectively | 7362 | 8075 |
| Goodwill | 12815 | 12815 |
| Operating lease right-of-use assets | 7833 | 8442 |
| Other non-current assets | 614 | 407 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total assets | $196591 | $217094 |
| **Liabilities and Stockholders' Equity** |  |  |
| Current liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | $16103 | $10522 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | 7315 | 7197 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued commissions | 6215 | 10121 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued compensation | 7172 | 6575 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other liabilities | 4103 | 510 |
| Total current liabilities | 40908 | 34925 |
| Long-term debt, net | 53529 | 53306 |
| Operating lease liabilities, net of current portion | 12930 | 15934 |
| Other long-term liabilities | 37 | 37 |
| Total liabilities | 107404 | 104202 |
| Commitments and contingencies (Note 7) |  |  |
| Stockholders' equity |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $0.001 par value, 5,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued as of September 30, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Common stock, $0.001 par value, 300,000,000 shares authorized; 63,846,382 and 62,385,101 shares issued as of September 30, 2025 and December 31, 2024, respectively | 64 | 62 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 329746 | 303004 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (239598) | (189990) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss) income | 83 | 97 |
| &nbsp;&nbsp;&nbsp;&nbsp;Treasury stock, at cost; 141,572 and 23,391 shares as of September 30, 2025 and December 31, 2024, respectively | (1108) | (281) |
| Total stockholders' equity | 89187 | 112892 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $196591 | $217094 |

---

The accompanying notes are an integral part of these condensed financial statements.

------

**TREACE MEDICAL CONCEPTS, INC.**

**Condensed Statements of Operations and Comprehensive Loss** 

**(in thousands, except share and per share amounts)** 

**(unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Revenue | $50214 | $45086 | $150171 | $140649 |
| Cost of goods sold | 10508 | 8954 | 30820 | 27862 |
| Gross profit | 39706 | 36132 | 119351 | 112787 |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 34421 | 32775 | 103627 | 110784 |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 4680 | 4963 | 15740 | 15379 |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 16281 | 13528 | 48216 | 42108 |
| Total operating expenses | 55382 | 51266 | 167583 | 168271 |
| Loss from operations | (15676) | (15134) | (48232) | (55484) |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 634 | 1067 | 2250 | 3978 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1338) | (1313) | (3970) | (3942) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 92 | 20 | 344 | 206 |
| Other non-operating income (expense), net | (612) | (226) | (1376) | 242 |
| Net loss | $(16288) | $(15360) | $(49608) | $(55242) |
| Other comprehensive income (loss) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized gain (loss) on marketable securities | 33 | 217 | (14) | 28 |
| Comprehensive loss | $(16255) | $(15143) | $(49622) | $(55214) |
| Net loss per share, basic and diluted | $(0.26) | $(0.25) | $(0.79) | $(0.89) |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted-average shares used in computing net loss per share, basic and diluted | 63515372 | 62229463 | 63069810 | 62035293 |

---

The accompanying notes are an integral part of these condensed financial statements.

------

**TREACE MEDICAL CONCEPTS, INC.** 

**Condensed Statements of Stockholders' Equity**

**(in thousands, except share amounts)** 

**(unaudited)**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  |  |  |  | **Accumulated** |  |  |
|  |  |  | **Additional** |  | **Other** |  | **Total** |
|  | **Common Stock** | **Common Stock** | **Paid-In** | **Accumulated** | **Comprehensive** | **Treasury** | **Stockholders'** |
|  | **Outstanding Shares** | **Amount** | **Capital** | **Deficit** | **Income (Loss)** | **Stock** | **Equity** |
| **Balances at December 31, 2024** | 62361710 | $62 | $303004 | $(189990) | $97 | $(281) | $112892 |
| Issuance of common stock upon exercise of stock options | 82829 | 1 | 118 |  |  |  | 119 |
| Issuance of common stock for vesting of restricted stock units | 499572 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 8693 |  |  |  | 8693 |
| Net loss |  |  |  | (15922) |  |  | (15922) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | (40) |  | (40) |
| Shares directly withheld from employees for tax payment | (52605) |  |  |  |  | (401) | (401) |
| **Balances at March 31, 2025** | 62891506 | $63 | $311815 | $(205912) | $57 | $(682) | $105341 |
| Issuance of common stock upon exercise of stock options | 87313 |  | 116 |  |  |  | 116 |
| Issuance of common stock for vesting of restricted stock units | 65389 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 9577 |  |  |  | 9577 |
| Net loss |  |  |  | (17398) |  |  | (17398) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | (7) |  | (7) |
| Shares directly withheld from employees for tax payment | (1894) |  |  |  |  | (14) | (14) |
| **Balances at June 30, 2025** | 63042314 | $63 | $321508 | $(223310) | $50 | $(696) | $97615 |
| Issuance of common stock upon exercise of stock options | 139570 | 1 | 240 |  |  |  | 241 |
| Issuance of common stock for vesting of restricted stock units | 586608 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 7998 |  |  |  | 7998 |
| Net loss |  |  |  | (16288) |  |  | (16288) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | 33 |  | 33 |
| Shares directly withheld from employees for tax payment | (63682) |  |  |  |  | (412) | (412) |
| **Balances at September 30, 2025** | 63704810 | $64 | $329746 | $(239598) | $83 | $(1108) | $89187 |
| **Balances at December 31, 2023** | 61749654 | $62 | $271973 | $(134247) | $163 | $(13) | $137938 |
| Issuance of common stock upon exercise of stock options | 20294 |  | 52 |  |  |  | 52 |
| Issuance of common stock for vesting of restricted stock units | 177610 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 7408 |  |  |  | 7408 |
| Net loss |  |  |  | (18676) |  |  | (18676) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | (94) |  | (94) |
| Shares directly withheld from employees for tax payment | (18386) |  |  |  |  | (237) | (237) |
| **Balances at March 31, 2024** | 61929172 | $62 | $279433 | $(152923) | $69 | $(250) | $126391 |
| Issuance of common stock upon exercise of stock options | 209288 |  | 311 |  |  |  | 311 |
| Issuance of common stock for vesting of restricted stock units | 36781 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 6740 |  |  |  | 6740 |
| Net loss |  |  |  | (21206) |  |  | (21206) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | (95) |  | (95) |
| **Balances at June 30, 2024** | 62175241 | $62 | $286484 | $(174129) | $(26) | $(250) | $112141 |
| Issuance of common stock upon exercise of stock options | 35371 |  | 8 |  |  |  | 8 |
| Issuance of common stock for vesting of restricted stock units | 64759 |  |  |  |  |  |  |
| Share-based compensation expense |  |  | 7900 |  |  |  | 7900 |
| Net loss |  |  |  | (15360) |  |  | (15360) |
| Unrealized gain (loss) on available-for-sale marketable securities |  |  |  |  | 217 |  | 217 |
| **Balances at September 30, 2024** | 62275371 | $62 | $294392 | $(189489) | $191 | $(250) | $104906 |

---

The accompanying notes are an integral part of these condensed financial statements.

------

**TREACE MEDICAL CONCEPTS, INC.** 

**Condensed Statements of Cash Flows** 

**(in thousands)**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net loss | $(49608) | $(55242) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating<br> activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization expense | 7815 | 6182 |
| &nbsp;&nbsp;&nbsp;&nbsp;Provision for allowance for credit losses | 512 | 2381 |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation expense | 26268 | 22048 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-cash lease expense | 1689 | 607 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization of debt issuance costs | 223 | 223 |
| &nbsp;&nbsp;&nbsp;&nbsp;Amortization (accretion) of premium (discount) on marketable securities, net | (119) | (918) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 750 | 180 |
| Net changes in operating assets and liabilities, net of acquisitions |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | 7428 | 11505 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory | (2169) | (14366) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses and other assets | (531) | 838 |
| &nbsp;&nbsp;&nbsp;&nbsp;Other non-current assets | (303) | (312) |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease liabilities | (2382) | (147) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 5581 | 6814 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued liabilities | (3191) | (12753) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other, net | 93 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) operating activities | (7944) | (32960) |
| **Cash flows from investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of available-for-sale marketable securities | (34889) | (52890) |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and maturities of available-for-sale marketable securities | 49593 | 93363 |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (11119) | (8519) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 3585 | 31954 |
| **Cash flows from financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from insurance premium financing | 1553 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Payments on insurance premium financing | (507) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from exercise of employee stock options | 476 | 371 |
| &nbsp;&nbsp;&nbsp;&nbsp;Taxes from withheld shares | (827) | (237) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) financing activities | 695 | 134 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash and cash equivalents | (3664) | (872) |
| Cash and cash equivalents at beginning of period | 11350 | 12982 |
| Cash and cash equivalents at end of period | $7686 | $12110 |
| **Supplemental disclosure of cash flow information** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash paid for interest | $3754 | $3732 |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating lease right-of-use asset and lease liability adjustment due to lease incentive | $— | $88 |
| **Noncash investing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Unrealized (gains) losses, net on marketable securities | $14 | $(28) |
| **Noncash financing activities** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal cost financing | $752 | $— |

---

The accompanying notes are an integral part of these condensed financial statements.

------

**TREACE MEDICAL CONCEPTS, INC.**

**Notes to Condensed Financial Statements**

**(unaudited)**

**1. Formation and Business of the Company**

Treace Medical Concepts, Inc. (the "Company") is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. The Company has pioneered and patented the Lapiplasty<sup>®</sup> 3D Bunion Correction System–a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, the Company has expanded its product offerings to continue to execute its strategy of becoming a comprehensive bunion solutions company and further penetrating the bunion market opportunity. The Company operates from its corporate headquarters located in Ponte Vedra, Florida.

**2. Summary of Significant Accounting Policies**

The Company prepared the unaudited interim condensed financial statements included in this report in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and the rules and regulations of the Securities and Exchange Commission ("SEC") related to quarterly reports on Form 10-Q.

## *Basis of Presentation* 
The condensed financial statements have been prepared on the same basis as the Company's annual financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 27, 2025. The condensed financial statements included herein reflect all adjustments, including normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the financial position, results of operations and cash flows for the periods presented. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results that may be expected for future quarters or for the fiscal year ending December 31, 2025.

Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Updates ("ASU") of the Financial Accounting Standards Board ("FASB").

## *Use of Estimates* 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although these estimates are based on the Company's knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Significant estimates and assumptions include valuation of intangible assets and goodwill, reserves and write-downs related to accounts receivable, inventories, the recoverability of long-term assets, deferred tax assets and related valuation allowances, contingencies, and stock-based compensation.

***Concentration of Credit Risk*** 

Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash, cash equivalents, marketable securities, and accounts receivable. The Company maintains its cash with established financial institutions and has exposure for balances in excess of the Federal Deposit Insurance Corporation insured limits. The Company's available-for-sale securities portfolio primarily consists of U.S. treasury and agency securities, money market funds, commercial paper, Yankee CDs, high credit quality asset-backed securities and corporate debt securities. The Company's investment policy requires its available-for-sale securities to meet certain criteria including investment type, credit ratings, and a maximum portfolio duration of one year.

The Company earns revenue from the sale of its products to customers such as hospitals, ambulatory surgery centers, and stocking distributors. The Company's accounts receivable are derived from revenue earned from customers. On

------

September 30, 2025 and December 31, 2024, no customer accounted for more than 10% of accounts receivable. For the three and nine months ended September 30, 2025 and 2024, there were no customers that represented 10% or more of revenue.

***Segments***

The Company is a single reportable segment entity, which is in the business of designing, manufacturing, and marketing medical devices for surgeons, hospitals, and ambulatory surgery centers related to the surgical management of bunion and related midfoot deformities. The Company's chief executive officer is the chief operating decision maker ("CODM"). The CODM regularly reviews entity-wide net income and operating results compared to budget and forecast information to assess the Company's performance and to allocate resources for its single reporting segment. The measure of profit or loss is reported in the Condensed Statements of Operations and Comprehensive Loss. The measure of segment assets is reported on the Company's Condensed Balance Sheets. The Company does not have any intra-entity sales or transfers. All long-lived assets are maintained in the United States.

***Rental Income***

The Company recorded rental income for its subleases of $0.1 million and $0.1 million for the three months ended September 30, 2025 and 2024, respectively. The Company recorded rental income for its subleases of $0.4 million and $0.3 million for the nine months ended September 30, 2025 and 2024, respectively. All subleases are classified as operating leases.

**3. Recent Accounting Pronouncements**

***Recent Accounting Pronouncements Not Yet Adopted***

In December 2023, the FASB issued ASU 2023-09, *Income Taxes (Topic 740) ("ASC 740")*. The update requires all public business entities on an annual basis to (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold and an explanation, if not otherwise evident, of the individual reconciling items disclosed, such as the nature, effect, and underlying causes of the reconciling items and the judgment used in categorizing the reconciling items. In addition, the update requires certain new disclosures of the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and the amount of income taxes paid (net of refunds received) disaggregated by individual jurisdictions in which income taxes paid is equal to or greater than five percent of total income taxes paid (net of refunds received). Other new disclosures required include income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) from continuing operations disaggregated by federal, state, and foreign. The new guidance is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The amendments are to be applied on a prospective basis, with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its financial statements and related disclosures.

In November 2024, the FASB issued ASU 2024-03, *Income Statement*–*Reporting Comprehensive Income*–*Expense Disaggregation Disclosures Topic 220-40 ("ASC 220-40").* The update requires all public business entities at interim and annual reporting periods to disclose in (1) a tabular format the amounts of certain specified natural expenses included in each relevant expense caption: the purchases of inventory, employee compensation, depreciation, and intangible asset amortization, (2) a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated, and (3) the total amount of selling expenses and an entity's definition of selling expenses annually. The new guidance is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. Early adoption is permitted. The amendments are to be applied on a prospective basis, with retrospective application permitted. The Company is currently evaluating the impact of the new standard on its financial statements and related disclosures.

In September 2025, the FASB issued ASU 2025-06, *Intangibles–Goodwill and Other–Internal-Use Software Topic 350-40: Targeted Improvements to the Accounting for Internal-Use Software ("ASC 350-40")*. The update clarifies and modernizes the accounting for costs related to internal-use software. The guidance removes all references to project stages in ASC 350-40 and clarifies the threshold entities should apply to begin capitalizing costs. The new guidance is effective for annual periods beginning after December 15, 2027, and interim periods within those years. Early adoption is permitted. The amendments are to be applied on a prospective, retrospective, or modified transition basis. The Company is currently evaluating the impact of the new standard on its financial statements and related disclosures.

------

**4. Fair Value Measurements** 

Assets and liabilities recorded at fair value in the condensed financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities are as follows:

Level 1–Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access as of the measurement date.

Level 2–Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3–Unobservable inputs for the asset or liability only used when there is little, if any, market activity for the asset or liability at the measurement date. This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.

*Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis*–The following assets and liabilities are measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Cash equivalents |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $2525 | $— | $— | $2525 |
| Short-term marketable securities at fair value |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and government agencies | 10228 |  |  | 10228 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 23989 |  | 23989 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities |  | 12163 |  | 12163 |
| &nbsp;&nbsp;&nbsp;&nbsp;Yankee CD |  | 3350 |  | 3350 |
| Total assets | $12753 | $39502 | $— | $52255 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Level 1** | **Level 2** | **Level 3** | **Total** |
| Assets: |  |  |  |  |
| Cash equivalents |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | $4798 | $— | $— | $4798 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 1197 |  | 1197 |
| Short-term marketable securities at fair value |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and government agencies | 10008 |  |  | 10008 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper |  | 495 |  | 495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 32269 |  | 32269 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities |  | 14781 |  | 14781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Yankee CD |  | 6774 |  | 6774 |
| Total assets | $14806 | $55516 | $— | $70322 |

---

The carrying amounts of the Company's money market funds classified as cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities, approximate their fair value due to the short-term nature of these assets and liabilities. Based on the borrowing rates currently available to the Company for debt with similar terms and consideration of default and credit risk, the carrying value of the term loan approximates fair value.

The Company's available-for-sale securities portfolio may consist of investments in U.S. treasury and government agency securities, commercial paper, corporate debt securities, asset-backed securities, and Yankee CDs. Yankee CDs are certificates of deposit issued in the United States by a branch of a foreign bank and are denominated in U.S. dollars. The fair value of Level 1 securities is determined on trade prices in active markets for identical assets. The fair value of Level 2 securities is determined using valuation models using inputs that are observable either directly or indirectly, such as quoted prices for

------

similar assets, interest rates, yield curves, credit spreads, default rates, loss severity, broker and dealer quotes, as well as other relevant economic measures.

There were no assets or liabilities measured at fair value on a nonrecurring basis as of September 30, 2025 and December 31, 2024.

**5. Balance Sheet Components**

## *Cash and Cash Equivalents* 
The Company's cash and cash equivalents consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| Cash | $5161 | $5355 |
| Cash equivalents: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Money market funds | 2525 | 4798 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt |  | 1197 |
| Total cash and cash equivalents | $7686 | $11350 |

---

## *Marketable Securities* 
The Company's available-for-sale marketable securities consisted of the following (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** | **September 30, 2025** |
|  | **Amortized Cost** | **Gross Unrealized Gains** | **Gross Unrealized Losses** | **Fair Value** |
| Marketable securities—short-term |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and government agencies | $10218 | $10 | $— | $10228 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt | 23934 | 55 |  | 23989 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities | 12145 | 18 |  | 12163 |
| &nbsp;&nbsp;&nbsp;&nbsp;Yankee CD | 3350 |  |  | 3350 |
| Total marketable securities—short-term | $49647 | $83 | $— | $49730 |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** | **December 31, 2024** |
|  | **Amortized Cost** | **Gross Unrealized Gains** | **Gross Unrealized Losses** | **Fair Value** |
| Marketable securities—short-term |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;U.S. treasury and government agencies | $9998 | $10 | $— | $10008 |
| &nbsp;&nbsp;&nbsp;&nbsp;Commercial paper | 495 |  |  | 495 |
| &nbsp;&nbsp;&nbsp;&nbsp;Corporate debt | 32216 | 55 | (2) | 32269 |
| &nbsp;&nbsp;&nbsp;&nbsp;Asset-backed securities | 14747 | 35 | (1) | 14781 |
| &nbsp;&nbsp;&nbsp;&nbsp;Yankee CD | 6774 |  |  | 6774 |
| Total marketable securities—short-term | $64230 | $100 | $(3) | $64327 |

---

As of September 30, 2025, there were no available-for-sale securities with unrealized losses greater than 12 months. An allowance for credit losses was not required for available-for-sale securities as of September 30, 2025 and December 31, 2024.

As of September 30, 2025, the Company had no plans to sell securities with unrealized losses, and believes it is more likely than not that it would not be required to sell such securities before recovery of their amortized cost. For the three and nine months ended September 30, 2025 and 2024, there were no material gains or losses from sales of available-for-sale securities.

As of September 30, 2025 and December 31, 2024, accrued interest of $0.6 million and $0.6 million, respectively, is excluded from the amortized cost basis of available-for-sale securities in the tables above and is recorded in prepaid expenses and other current assets on the Condensed Balance Sheets.

------

As of September 30, 2025, all marketable securities mature within two years, except for asset-backed securities. Asset-backed securities are not due at a single maturity date. As such, these securities were not included.

## *Property and equipment, net* 
The Company's property and equipment, net consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| Furniture and fixtures | $2565 | $2565 |
| Construction in progress | 896 | 612 |
| Machinery and equipment | 3712 | 3081 |
| Capitalized surgical equipment<sup>1</sup> | 31541 | 22669 |
| Computer equipment | 1226 | 1160 |
| Leasehold improvements | 10580 | 10244 |
| Software and website development | 1227 | 927 |
| Total property and equipment | 51747 | 41258 |
| Less: accumulated depreciation and amortization | (21777) | (15305) |
| Property and equipment, net | $29970 | $25953 |

---

<sup>1</sup> Capitalized surgical equipment includes $25.2 million and $18.3 million that is ready for its intended use and have started depreciating and $6.3 million and $4.4 million that is not ready for its intended use and have not started depreciating as of September 30, 2025 and December 31, 2024, respectively.

Depreciation and amortization expense on property and equipment was $2.5 million and $1.9 million for the three months ended September 30, 2025 and 2024, respectively. Depreciation and amortization expense on property and equipment was $7.1 million and $5.5 million for the nine months ended September 30, 2025 and 2024, respectively.

The Company did not record impairment charges for its property and equipment, net for the nine months ended September 30, 2025 and 2024.

## *Accrued liabilities* 
Accrued liabilities consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| Accrued royalties expense | $1688 | $2259 |
| Accrued interest | 413 | 420 |
| Accrued professional services | 2694 | 337 |
| Accrued compensation expense for RPM-3D earn-out<sup>1</sup> |  | 2125 |
| Other accrued expense | 2520 | 2056 |
| Total accrued liabilities | $7315 | $7197 |

---

<sup>1</sup> On June 12, 2023, the Company acquired certain assets of MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D") that included an earn-out payment related to the technological advancements and patent milestones, which was paid on January 15, 2025.

## *Other liabilities* 
Other liabilities consist of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| Current portion of operating lease liabilities | $2115 | $413 |
| Short-term debt<sup>1</sup> | 1798 |  |
| Other | 190 | 97 |
| Total other liabilities | $4103 | $510 |

---

<sup>l</sup> See Note 6, "Long-Term Debt," for information regarding the legal cost financing related to the lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. Short-term debt includes $0.8 million in financed legal costs as of September 30, 2025 and reflects the amount that may be called within the next twelve months. In addition, short-term debt includes $1.0 million of insurance premiums payable over the next nine months.

------

**6. Long-Term Debt** 

The Company's long-term debt consisted of the following (in thousands):

---

| | | |
|:---|:---|:---|
|  | **September 30,** | **December 31,** |
|  | **2025** | **2024** |
| *Revolving line of credit* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;MidCap revolving loan facility | $4000 | $4000 |
| *Term loans* |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;MidCap term loan facility | 50000 | 50000 |
| Total term and revolving loans | 54000 | 54000 |
| Less: debt discount and issuance costs | (471) | (694) |
| Total long-term debt, net | $53529 | $53306 |

---

As of September 30, 2025, future payments of long-term debt were as follows (in thousands):

---

| | |
|:---|:---|
| **Fiscal Year** |  |
| 2025 | $— |
| 2026 |  |
| 2027 | 54000 |
| Total principal payments | 54000 |
| Less: Unamortized debt discount and debt issuance costs | (471) |
| Total long-term debt, net | $53529 |

---

***MidCap Loan and Revolving Loan Facility***

On April 29, 2022, the Company entered into a five-year $150.0 million loan facility with entities affiliated with MidCap Financial Trust ("MidCap"), providing up to $120.0 million in a term loan facility and a $30.0 million revolving loan facility.

The term loan facility provides for a 60-month term loan up to $120.0 million in borrowing capacity to the Company, over four tranches. At term loan closing, the Company drew $50.0 million under tranche one. At September 30, 2025, all term loan tranches are expired and are no longer available to draw.

The revolving loan facility provides up to $30.0 million in borrowing capacity to the Company based on the borrowing base. The borrowing base is calculated based on certain accounts receivable and inventory assets. As of September 30, 2025, the borrowing base allows $23.2 million of remaining availability to the Company under the revolving loan facility, net of the $4.0 million balance drawn. The Company may request an increase in the revolving loan facility in an amount up to $20.0 million for a total commitment of up to $50.0 million. The Company is required to either (i) maintain a minimum drawn balance under the revolving loan facility or (ii) pay a minimum balance fee that is equal to the amount of the minimum balance deficit multiplied by the applicable interest rate during the period. If the outstanding balance under the revolving loan facility exceeds the lesser of (i) 50% of the revolving borrowing capacity or (ii) 50% of the borrowing base, or the Company is in default, MidCap will apply funds collected from the Company's lockbox account to reduce the outstanding balance of the revolving loan facility ("Lockbox Deductions"). As of September 30, 2025, the Company's borrowing level has not activated the Lockbox Deductions, nor is it expected to for the next 12 months; therefore, the Company has determined that the revolving loan balance is long-term debt.

The loans bear interest at an annual rate based on a 30-day forward looking secured overnight financing rate plus 0.10% (subject to a floor of 1.0% and a cap of 3.0% for both loan agreements) plus (i) 6.0% under the term loan agreement and (ii) 4.0% under the revolving loan facility. Interest is payable monthly in arrears on the first day of each month and on the maturity of the loan agreements. The term loan and the revolving loan facility are accruing interest as of September 30, 2025 at the capped interest rates of 9% and 7%, respectively. The Company is obligated to pay interest only for the first 48 months and straight-line amortization for the remaining 12 months, subject to the Company's option to extend the initial interest-only period by 12 months to 60 months total if the Company's trailing twelve-month revenue is at or above certain levels. As of September 30, 2025, the Company meets the revenue levels required to extend the initial interest period to 60 months and we intend to extend the interest-only period. If the term loan is repaid before the maturity date or the revolving loan facility is terminated before the end of its term, the prepayment fees are 3.0% of the amount repaid in the first year, 2.0% in the second year and 1.0% in the third year and thereafter, and a final payment fee of 3.0% of the amount borrowed is due under the term loan. The revolving loan facility prepayment fees are based on the revolving loan commitment amount.

------

The loans are secured by substantially all of the Company's assets, including intellectual property. The loan agreements and other ancillary loan documents contain customary representations and warranties and affirmative and negative covenants. Under the loan agreements, the Company is not required to meet any minimum level of revenue if liquidity (defined as unrestricted cash plus undrawn availability under the revolving loan agreement) is greater than the outstanding balance under the term loan. If liquidity falls below such outstanding balance, then the Company is subject to a minimum trailing twelve-month revenue covenant. The Company is not subject to this covenant at September 30, 2025.

***Legal Cost Financing*** 

On March 25, 2025, the Company entered into an agreement with its primary legal counsel related to the pending patent and antitrust dispute with Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") to defer payment of certain legal costs incurred in 2025 and 2026 related to the Stryker dispute. The agreement anticipates that the amount financed by the Company would not exceed $5.0 million over this two-year period. The deferred portion of the legal costs bear interest at 10% per annum. The total principal and interest financed is scheduled to be repaid in twelve equal monthly installments beginning January 2027. However, if certain thresholds for the currently paid portion of legal costs are not reached in 2025 and 2026, primary counsel has the option to require a portion of the deferred balances up to the current threshold amount to be reallocated to currently due. The amount of legal costs that are not deferred are due according to normal billing terms and are subject to certain contractual thresholds. All current and deferred legal costs are expensed as incurred. All amounts financed as of September 30, 2025 are classified as current debt and are included in other liabilities on the Condensed Balance Sheets as the primary legal counsel has the option to reallocate the deferred legal costs to currently due up to the threshold. See Note 5, "Balance Sheet Components," for additional information on the amounts of the deferred legal costs.

**7. Commitments and Contingencies** 

## *License and Royalty Commitments* 

As of September 30, 2025 and 2024, the Company has royalty agreements with certain surgeon consultants. The Company recognized royalty expense for the three months ended September 30, 2025 and 2024 of $1.6 million and $1.4 million, respectively, resulting in an aggregate royalty rate of 3.1% and 3.2%, respectively. The Company recognized royalty expense for the nine months ended September 30, 2025 and 2024 of $4.7 million and $4.6 million, respectively, resulting in an aggregate royalty rate of 3.1% and 3.3%, respectively.

***Contingencies***

In accordance with applicable accounting standards, the Company establishes an accrued liability for litigation contingencies when those matters present loss contingencies that are both probable and can be reasonably estimated. The Company discloses the nature of the contingency when management believes there is at least a reasonable possibility that the outcome may be material to the Company's financial statements and, where feasible, an estimate of the possible loss. In such cases, there still may be an exposure to loss in excess of any amounts reasonably estimated and accrued. When a loss contingency is not both probable and reasonably estimable, the Company does not establish an accrued liability, but continues to monitor, in conjunction with any outside counsel handling a matter, further developments that would make such loss contingency both probable and reasonably estimable. Once the Company establishes an accrued liability with respect to a loss contingency, the Company continues to monitor the matter for further developments that could affect the amount of the accrued liability that has been previously established, and any appropriate adjustments are made each quarter.

On April 11, 2025, a shareholder filed a class action complaint in the United States District Court for the Middle District of Florida (captioned *McCluney v. Treace Medical Concepts, Inc. et al.* Case No. 3:25-cv-00390-WWB-PDB) against the Company and certain of its officers on behalf of all persons who purchased or otherwise acquired the Company's stock between May 8, 2023 and May 7, 2024 alleging that the Company and certain of its officers violated the federal securities laws by making false or misleading statements and failing to disclose material adverse facts about our business, operations and prospects. The plaintiffs seek unspecified monetary damages, costs, and attorneys' fees. On July 1, 2025, the court

------

appointed the lead plaintiff and lead counsel. The plaintiff filed an amended complaint on July 31, 2025, and the Company filed a motion to dismiss on September 5, 2025. The action is in the preliminary stage. The Company disputes the allegations in the complaint and intends to defend against this complaint vigorously. Based on the preliminary nature of the proceedings in this action, the outcome remains uncertain, and the Company cannot reasonably estimate the potential impact, if any, on our business or financial statements at this time. The Company is insured for Directors and Officers liability for amounts in excess of the retention and up to the policy limits.

There were no accrued contingent liabilities as of September 30, 2025 and December 31, 2024.

**8. Stockholders' Equity**

## *Stock Options* 
During the nine months ended September 30, 2025, the Company did not grant stock options to employees. During the nine months ended September 30, 2024, the Company granted stock options to employees to purchase 852,220 shares of the Company's common stock. The weighted-average grant-date fair value of the employee stock options granted during the nine months ended September 30, 2024 was $4.96 per share. The Company expects to reduce the use of stock options as long-term equity awards for its executives.

***Restricted Stock Units***

During the nine months ended September 30, 2025 and 2024, the Company granted 3,127,114 and 3,370,462 restricted stock units ("RSUs"), respectively. The weighted average grant-date fair value of RSUs granted during the nine months ended September 30, 2025 and 2024 was $8.27 and $9.09 per share, respectively.

## *Performance Share Units* 
The Company generally grants performance-based restricted stock unit ("PSU") awards subject to market and service vesting conditions to certain executives under the Company's 2021 Incentive Award Plan. The actual number of PSUs that will vest at the end of the measurement period is generally determined based on the Company's total stockholder return ("TSR") ranking relative to the TSR of a published index of the Company's peers. The measurement period for its outstanding awards is generally three years. The grant date fair value of each target PSU award was determined using a Monte Carlo valuation model or the grant date fair value. Over the performance period, if the service vesting conditions are met, the actual number of PSUs earned may vary from zero, if performance thresholds are not met, to as much as 200% of target PSUs depending on the grant year.

During the nine months ended September 30, 2025 and 2024, the Company granted PSUs for 1,160,625 and 453,375 shares, respectively, at target performance levels. The weighted average grant-date fair value of the PSUs granted during the nine months ended September 30, 2025 and 2024 was $9.13 and $18.89 per share, respectively.

## *Share-Based Compensation Expense* 
Share-based compensation expense is reflected in the Condensed Statements of Operations and Comprehensive Loss as follows (in thousands):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Cost of goods sold | $130 | $91 | $327 | $272 |
| Sales and marketing expense | 1669 | 1764 | 5116 | 5052 |
| Research and development expense | 948 | 1152 | 3188 | 3174 |
| General and administrative expense | 5251 | 4893 | 17637 | 13550 |
| Total | $7998 | $7900 | $26268 | $22048 |

---

------

**9. Net Loss Per Share Attributable to Common Stockholders** 

The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders which is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding for the period. As the Company reported a net loss for the three and nine months ended September 30, 2025 and 2024, basic net loss per share attributable to common stockholders was the same as diluted net loss per share attributable to common stockholders as the inclusion of potentially dilutive shares would have been antidilutive if included in the calculation (in thousands, except share and per share amounts):

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| Numerator |  |  |  |  |
| Net loss | $(16288) | $(15360) | $(49608) | $(55242) |
| Denominator |  |  |  |  |
| Weighted-average common stock outstanding,<br> basic and diluted | 63515372 | 62229463 | 63069810 | 62035293 |
| Net loss per share attributable to common<br> stockholders, basic and diluted | $(0.26) | $(0.25) | $(0.79) | $(0.89) |

---

The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding because such securities have an antidilutive impact due to the Company's net loss, in common stock equivalent shares:

---

| | | |
|:---|:---|:---|
|  | **As of September 30,** | **As of September 30,** |
|  | **2025** | **2024** |
| Common stock options issued and outstanding | 7255136 | 7793815 |
| Unvested full value awards | 5906625 | 4157460 |
| Contingently issuable PSU shares | 1365491 |  |
| Total | 14527252 | 11951275 |

---

------

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

*You should read the following discussion and analysis of our financial condition and results of operations together with our condensed financial statements and related notes thereto included in this Quarterly Report on Form 10-Q (this "Quarterly Report") and our audited financial statements and related notes thereto for the year ended December 31, 2024, included in our Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC") on February 27, 2025 (our "Annual Report"). This discussion and other parts of this Quarterly Report contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions that are based on the beliefs of our management, as well as assumptions made by, and information currently available to, our management. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report under "Part I, Item 1A–Risk Factors," and in the section titled "Risk Factors" and elsewhere in this Quarterly Report*. *Please also see the section of this Quarterly Report titled "Special Note Regarding Forward-Looking Statements."* 

## Overview
We are a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. We have pioneered our proprietary Lapiplasty<sup>®</sup> 3D Bunion Correction System<sup>®</sup>–a combination of instruments, implants and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Although bunions are deformities typically caused by an unstable joint in the middle of the foot that leads to a three-dimensional ("3D") misalignment in the foot's anatomical structure, the majority of traditional surgical approaches focus on correcting the deformity from a two-dimensional ("2D") perspective and therefore fail to address the root cause of the disorder. To effectively restore the normal anatomy of bunion patients and improve clinical outcomes, we believe addressing the root cause of the bunion is critical, and have developed the Lapiplasty System to correct the deformity across all three anatomic dimensions. Our other products often used in conjunction with bunion surgery include the Adductoplasty<sup>®</sup> System, the Hammertoe PEEK Fixation System, the SpeedPlate<sup>®</sup> Rapid Compression Implant System, and specialized osteotomes and release instruments. In addition, we recently entered the metatarsal osteotomy segment with the Nanoplasty<sup>®</sup> and Percuplasty™ Procedures, which both allow for a 3D correction of the bunion through cosmetically appealing, minimally invasive solutions. With our Lapiplasty System, new osteotomy systems, and other complementary products, we are continuing to execute our strategy of becoming a comprehensive bunion solutions company and supporting further penetration into the bunion market opportunity. See the "Innovation and Growth" section below for more information on our new products.

We were formed in 2013, and since receiving 510(k) clearance for the Lapiplasty System in March 2015, we have expanded our bunion related products in the United States. We market and sell our products to surgeons, ambulatory surgery centers, hospitals, and stocking distributors. As part of our strategy for 2025, we began utilizing a limited number of stocking distributors in the first quarter of 2025. Our procedures can be performed in either hospital outpatient or ambulatory surgery center settings, and utilize existing, well-established reimbursement codes. We primarily market and sell our products through a combination of a direct employee sales force and independent sales agencies in the United States.

As of September 30, 2025, we had cash and cash equivalents of $7.7 million and marketable securities of $49.7 million available for sale to fund operations, an accumulated deficit of $239.6 million and $54.0 million of principal outstanding under our term loan and revolving loan agreements.

**Economic Environment**

The economy is expected to slow in the remainder of 2025 and 2026 amid continuing macroeconomic uncertainty. Inflation, recession fears, reduced consumer confidence, higher insurance deductibles and other costs, and other adverse economic conditions have and may continue to negatively impact consumer demand for our products that are used in elective surgeries. While we continuously work with suppliers to mitigate higher costs and continue to invest in our direct sales channel, patient education initiatives, clinical evidence and product innovations to build demand for our products, we expect these macroeconomic challenges to continue for the foreseeable future, which likely will impact the demand for our products and our results of operations. Adding to these uncertainties are the protracted government shutdown and evolving U.S. tariff policies on imports, along with retaliatory tariffs, that may change rapidly. While we expect that the tariffs are likely to increase our inventory costs and reduce gross margins, we do not expect these impacts to be material at the most recently announced tariff rates.

------

***Increased Competition***

Before we launched our flagship Lapiplasty System, there were no other products in the market that provided a 3D solution and specialized procedural instrumentation for traditionally freehand, difficult Lapidus surgeries. This allowed us to capitalize on our pioneering technology and grow our market share quickly. We are experiencing increased competition from the accelerating adoption of minimally invasive osteotomy solutions and from new Lapidus products, which has, and may continue to, negatively impact our growth rates, market share, and results of operations. In order to drive increased penetration into the bunion market, we have introduced new bunion systems, including two minimally invasive osteotomy systems and a great toe fusion system. While the adoption of these new systems is increasing, we generally sell them at lower average selling prices than our Lapiplasty System. To the extent we lose market share or experience further declines in sales of our Lapiplasty System and we are unable to sufficiently increase sales of our new bunion systems to offset the declines in sales of our Lapiplasty System, our revenues and results of operations will be adversely affected.

***Innovation and Growth*** 

We expect to continue to focus on long-term revenue growth through investments in our business and new products. In sales and marketing, we have dedicated meaningful resources to building a sales force and management team to support our future growth and to providing bunion-focused surgeon training and patient-focused outreach and education.

In research and development, our employee team and surgeon consultants are continually working on next-generation innovations for the surgical correction of bunions and other conditions that often present with bunions. In the fourth quarter of 2024, we began the limited market releases of the following new products: (1) the Nanoplasty and Percuplasty Systems, which are minimally-invasive 3D osteotomy systems; (2) IntelliGuide™ PSI Cut Guides for Lapiplasty and Adductoplasty Procedures, which are cut guides created specifically for an individual patient's foot anatomy; (3) the Micro-Lapiplasty<sup>®</sup> System, which is designed to allow the Lapiplasty Procedure to be performed through a minimally-invasive 2cm incision; (4) the Mini-Adductoplasty™ System, which is designed to allow the Adductoplasty midfoot correction procedure to be performed through an approximately 50% smaller incision; and (5) the SpeedMTP<sup>®</sup> Rapid Compression Implant, a specialized implant for addressing bunions through MTP fusions. In the first half of 2025, we began the limited market release of the SpeedAkin™ implant used in Akin osteotomy procedures, the SpeedPlate Micro-Quad implant, and four new single use osteotomes. We have continued to expand the commercial availability of these new products and to release other new solutions during 2025, including the Percuplasty™ MIS Power System, a specialized and scalable power drill that operates the single-use cutting burrs used in the Percuplasty™ procedure as well as other minimally invasive procedures throughout the foot, and biologics commonly used in foot and ankle fusion procedures. We plan to begin offering additional innovations in 2026, including the Lapiplasty Lightning platform designed to further increase the precision and speed of the Lapiplasty 3D correction, a new line of compression screws, and additional procedure specific SpeedPlate implants and sterile instruments.

***Intellectual Property Strategy***

We actively seek to protect the technology, inventions, and improvements that we consider important to our business using patents, trade secrets, trademarks and copyrights in the United States and foreign markets. As of September 30, 2025, our patent portfolio included 90 granted U.S. patents, with an additional 31 granted patents worldwide and over 175 pending patent applications. In keeping with our strategy of protecting our intellectual property rights, on October 14, 2024, we filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. (collectively, "Stryker") alleging infringement of 9 patents related to our innovative Lapiplasty 3D Bunion Correction technologies and unfair competition. The suit was filed in the United States District Court for the District of New Jersey, and seeks injunctive relief and damages. In addition, on May 12, 2025, we filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. (collectively, "ZB") alleging infringement of 4 patents related to our innovative Lapiplasty 3D Bunion Correction technologies. The suit was filed in the United States District Court for the District of Delaware and seeks injunctive relief and damages. On August 5, 2025, we filed an amended complaint alleging infringement of an additional patent.

## *Market Share Growth* 
The growth of our business depends on our ability to gain broader acceptance of our proprietary procedures and systems by successfully marketing and distributing these products. While surgeon adoption of our products and procedures remains critical to supporting revenue growth, hospital and ambulatory surgery center facility approvals are necessary for existing and future surgeon customers to access our products. To facilitate greater access to our products and support future sales growth, we intend to continue educating hospitals and facility administrators on the differentiated benefits associated with our procedures and systems, supported by our robust portfolio of clinical data on our existing procedures and additional clinical

------

data we expect to develop on our new products. To continue to build our market share, in 2025, we have added new commercial and sales leadership as well as experienced foot and ankle sales professionals to our team. While we have experienced overall increases in bunion procedure kit sales and in our market share, our flagship Lapiplasty System is expected to contribute less to our market share growth in future quarters, which could result in reduced revenues and impact our liquidity if product sales from our new bunion systems do not increase sufficiently to offset the decline in sales of the Lapiplasty System. If we are unable to successfully continue to commercialize our procedures and systems, we may not be able to generate sufficient revenue to achieve or sustain profitability. In the near term, we expect we will continue to operate at a loss, and we anticipate we will finance our operations principally through the use of our cash and cash equivalents, marketable securities, and expected revenues. We may also raise funds by incurring debt and through offerings of our capital stock.

## *Seasonality* 
We have experienced and expect to continue to experience seasonality in our business, with higher sales volumes in the fourth calendar quarter, historically accounting for approximately 30% to 40% of full year revenues, and lower sales volumes in the subsequent first calendar quarter. Our sales volumes in the fourth quarter tend to be higher as many patients elect to have surgery after meeting their annual deductible and having time to recover over the winter holidays. Our sales volumes in subsequent first calendar quarters also tend to be lower versus the prior year fourth quarters as a result of adverse weather and by resetting annual patient healthcare insurance plan deductibles, both of which may cause patients to delay elective procedures; however, in some years the first quarter may benefit from additional sales volumes when high patient demand for surgeries in the fourth quarter cannot be fully accommodated and those surgical procedures are rolled over into the first quarter. In addition to the seasonality noted above, we generally expect lower sales volumes in the second and third quarters than throughout the rest of the year as elective procedures generally decline during the spring and summer months.

***Coverage and Reimbursement*** 

Hospitals, ambulatory surgery centers and surgeons that purchase or use our products generally rely on third-party payors to reimburse for all or part of the costs and fees associated with procedures using our products. As a result, sales of our products depend, in part, on the extent to which the procedures using our products are covered by third-party payors, including government programs such as Medicare and Medicaid, private insurance plans and managed care programs. Based on historical claims data, more than 60% of all bunion surgical cases are paid by private payors.

Medicare payment rates to hospital outpatient departments are set under the Medicare hospital outpatient prospective payment system, which groups clinically similar hospital outpatient procedures and services with similar costs to ambulatory payment classifications ("APCs"). Each APC is assigned a single lump sum payment rate, which includes payment for the primary procedure as well as any integral, ancillary, and adjunctive services. The primary current procedure terminology ("CPT") codes for the Lapiplasty Procedure, CPT 28297 and CPT 28740, are grouped together under APC 5114. For Lapiplasty Procedures in which fusion is performed on multiple tarsometatarsal ("TMT") joints, CPT 28730 applies and is classified under APC 5115. For Adductoplasty Procedures in which fusion is performed on multiple TMT joints, either CPT 28730 or CPT 27835 applies and are classified under APC 5115. For the Nanoplasty and Percuplasty Procedures, CPT 28306 applies. For MTP fusions using the SpeedMTP implant or our other plates, CPT 28750 applies.

**Components of Our Results of Operations** 

## *Revenue* 
We currently generate revenue from the sale of our bunion implant kit systems, single-use sterile instruments, and other complementary products. Our systems bring together single-use implant kits, reusable instrument trays, and surgical techniques. We sell the kits and single-use instruments and other products to hospitals, ambulatory surgery centers, and stocking distributors in the United States through a network of employee sales representatives and independent sales agencies.

No single customer accounted for 10% or more of our revenue during the nine months ended September 30, 2025. We expect our revenue to increase in absolute dollars in the foreseeable future as we expand our product offerings, new accounts and trained physician base, and as existing physician customers that use our products perform more procedures using our products, although our rate of revenue growth may fluctuate from quarter to quarter due to a variety of factors, including seasonality, the macroeconomic environment and competition.

------

## *Cost of Goods Sold* 
Cost of goods sold consists primarily of direct costs for the purchase of our products from third-party manufacturers. Cost of goods sold also includes royalties, overhead, shipping costs, sterilization, and packaging. We expense all inventory provisions for excess, obsolete, and field losses as cost of goods sold. We evaluate the carrying value of our inventories in relation to historical sales, current inventory levels, and consideration of the life cycle of the product. A significant decrease in demand or development of products could result in an increase in the amount of excess or obsolete inventory on hand, which could lead to additional provisions. We expect our cost of goods sold to increase in absolute dollars in the foreseeable future to the extent more of our products are sold, though it may fluctuate from quarter to quarter.

## *Gross Profit and Gross Margin* 
We calculate gross profit as revenue less cost of goods sold, and gross margin as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily average selling prices, production, and ordering volumes, change in mix of customers, third-party manufacturing costs and cost-reduction strategies. We expect our gross profit to increase in the foreseeable future as our revenue grows, though our gross margin may fluctuate from quarter to quarter due to changes in average selling prices as we introduce new products, and as we adopt new manufacturing processes and technologies.

## *Operating Expenses* 

## *Sales and Marketing* 
Sales and marketing expenses consist primarily of compensation for personnel, including salaries, bonuses, benefits, sales commissions and share-based compensation, related to selling and marketing functions, surgical instrument expense, physician education programs, training, shipping costs related to sending products to our sales representatives, travel expenses, marketing initiatives including our direct-to-consumer outreach program and advertising, market research and analysis and conferences and trade shows.

## *Research and Development* 
Research and development ("R&D") expenses consist primarily of engineering, product development, clinical studies to develop and support our products, regulatory expenses, and other costs associated with products and technologies that are in development. These expenses include compensation for personnel, including salaries, bonuses, benefits and share-based compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation, and allocated facilities-related expenses.

## *General and Administrative* 
General and administrative expenses consist primarily of compensation for personnel, including salaries, bonuses, benefits, and share-based compensation, related to finance, information technology, legal and human resource functions, as well as professional services fees (including legal, audit and tax fees), insurance costs, general corporate expenses, and allocated facilities-related expenses.

## *Interest Income* 
Interest income consists of interest received on our money market funds and marketable securities.

## *Interest Expense* 
Interest expense consists of interest incurred and amortization of debt discount and issuance costs related to outstanding borrowings.

------

## Results of Operations

## *Comparison of the three and nine months ended September 30, 2025 and 2024* 
The following table summarizes our results of operations for the periods presented below ($ in thousands):

---

| | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Three Months Ended September 30,** | **Three Months Ended September 30,** | **Change** | **Change** | **Change** | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** | **Change** | **Change** | **Change** |
|  | **2025** | **2024** | **Amount** | **%** | **%** | **2025** | **2024** | **Amount** | **%** | **%** |
| Revenue | $50214 | $45086 | $5128 |  | 11.4% | $150171 | $140649 | $9522 |  | 6.8% |
| Cost of goods sold | 10508 | 8954 | 1554 |  | 17.4% | 30820 | 27862 | 2958 |  | 10.6% |
| Gross profit | 39706 | 36132 | 3574 |  | 9.9% | 119351 | 112787 | 6564 |  | 5.8% |
| Operating expenses |  |  |  |  |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales and marketing | 34421 | 32775 | 1646 |  | 5.0% | 103627 | 110784 | (7157) |  | (6.5)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 4680 | 4963 | (283) |  | (5.7)% | 15740 | 15379 | 361 |  | 2.3% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 16281 | 13528 | 2753 |  | 20.4% | 48216 | 42108 | 6108 |  | 14.5% |
| Total operating expenses | 55382 | 51266 | 4116 |  | 8.0% | 167583 | 168271 | (688) |  | (0.4)% |
| Loss from operations | (15676) | (15134) | (542) |  | 3.6% | (48232) | (55484) | 7252 |  | (13.1)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 634 | 1067 | (433) |  | (40.6)% | 2250 | 3978 | (1728) |  | (43.4)% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (1338) | (1313) | (25) |  | 1.9% | (3970) | (3942) | (28) |  | 0.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income, net | 92 | 20 | 72 | \* | \*% | 344 | 206 | 138 |  | 67.0% |
| Other non-operating income (expense), net | (612) | (226) | (386) |  | 170.8% | (1376) | 242 | (1618) | \* | \*% |
| Net loss | $(16288) | $(15360) | $(928) |  | 6.0% | $(49608) | $(55242) | $5634 |  | (10.2)% |

---

\* Not meaningful

*<u>Comparison of the three months ended September 30, 2025 and 2024</u>*

*Revenue.* Revenue increased by $5.1 million, or 11.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily driven by an increase in the number of bunion procedure kits sold, partially offset by lower average selling prices of our newest bunion procedure kits. While the number of bunion procedure kits sold are increasing overall, our flagship Lapiplasty System is experiencing lower sales primarily due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery due to macroeconomic conditions. Revenue for the three months ended September 30, 2025 included $6.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders, compared to no stocking distributor sales during the same period in 2024. As of the end of third quarter, our stocking distributors have purchased their initial stock of inventory; therefore, we do not expect sales at this level in future quarters.

*Cost of Goods Sold, Gross Profit and Gross Margin.* Cost of goods sold increased by $1.6 million, or 17.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in cost of goods sold was primarily due to a $1.2 million increase in direct cost of goods sold resulting from increased sales. During the three months ended September 30, 2025, gross profit increased by $3.6 million, or 9.9%, as compared to the same period in 2024, due to increased sales. Gross profit margin for the three months ended September 30, 2025 decreased from 80.1% to 79.1%, as compared to the same period in 2024, primarily due to lower margin sales to stocking distributors, partially offset by a shift in product mix.

*Sales and Marketing Expenses.* Sales and marketing expenses increased by $1.6 million, or 5.0%, for the three months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses increased due to a $1.2 million increase in commissions, a $0.5 million increase in surgical instrument expense from higher volume of surgical instruments, a $0.4 million increase in payroll and related costs, a $0.4 million increase for surgeon training and clinical-related expenses, and a $0.2 million increase from higher costs for conferences and events, partially offset by a $1.3 million decrease in direct to consumer advertising costs. Of the $0.4 million increase in payroll and related costs, $1.0 million was related to a non-recurring restructuring charge that includes severance and other post-employment benefits, partially offset by a decrease in other payroll-related costs.

*Research and Development Expenses.* R&D expenses decreased by $0.3 million, or 5.7%, for the three months ended September 30, 2025 as compared to the same period in 2024. The decrease in R&D expenses was primarily due to a $0.2 million decrease in purchases of prototypes.

------

*General and Administrative Expenses.* General and administrative expenses increased by $2.8 million, or 20.4%, for the three months ended September 30, 2025 as compared to the same period in 2024. The increase in general and administrative expenses was due to a $2.9 million increase in legal fees primarily driven by ongoing litigation matters, partially offset by a $0.2 million decrease in the provision for allowance for credit losses.

*Interest Income.* Interest income decreased $0.4 million, or 40.6%, for the three months ended September 30, 2025 as compared to the same period in 2024. The decrease in interest income was primarily due to lower balances invested in marketable securities during the current year period.

*<u>Comparison of the nine months ended September 30, 2025 and 2024</u>*

*Revenue.* Revenue increased by $9.5 million, or 6.8%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase was primarily driven by an increase in the number of bunion procedure kits sold, partially offset by lower average selling prices of our newest bunion procedure kits. While the number of bunion procedure kits sold are increasing overall, our flagship Lapiplasty System is experiencing lower sales primarily due to evolving surgeon preferences for minimally invasive osteotomy procedures, competition, and lower patient demand for elective bunion surgery related to macroeconomic conditions. Revenue for the nine months ended September 30, 2025 included $11.0 million in sales to stocking distributors, a majority of which was attributable to initial stocking orders, compared to no stocking distributor sales during the same period in 2024. As of the third quarter, our stocking distributors have purchased their initial stock of inventory; therefore, we do not expect sales at the level experienced during the third quarter of 2025 in future quarters.

*Cost of Goods Sold, Gross Profit and Gross Margin.* Cost of goods sold increased by $3.0 million, or 10.6%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in cost of goods sold was primarily due to a $1.7 million increase in direct costs of goods sold resulting from increased sales and a $1.1 million increase in inventory provisions. During the nine months ended September 30, 2025, gross profit increased by $6.6 million, or 5.8%, as compared to the same period in 2024, due to increased sales. Gross profit margin for the nine months ended September 30, 2025 decreased from 80.2% to 79.5%, as compared to the same period in 2024, primarily due to lower margin sales to stocking distributors and increases in inventory provisions, partially offset by a shift in product mix.

*Sales and Marketing Expenses.* Sales and marketing expenses decreased by $7.2 million, or 6.5%, for the nine months ended September 30, 2025 as compared to the same period in 2024. Sales and marketing expenses decreased due to a $7.6 million reduction in direct to consumer advertising costs and a $6.0 million decrease in payroll and related costs primarily from optimizing the size and structure of our direct employee sales force, partially offset by a $2.7 million increase for surgeon training and clinical-related expenses, a $1.7 million increase in commissions, and a $1.4 million increase in surgical instrument expense from higher volume of surgical instruments.

*Research and Development Expenses.* R&D expenses increased by $0.4 million, or 2.3%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in R&D expenses was primarily due to a $0.9 million increase in payroll and related costs resulting from increased headcount of R&D personnel, partially offset by a $0.5 million decrease in compensation expense related to the milestone obligation for our acquisition of MIOS Marketing, LLC d/b/a RedPoint Medical3D ("RPM-3D") that was incurred in the nine months ended September 30, 2024, but not in the nine months ended September 30, 2025.

*General and Administrative Expenses.* General and administrative expenses increased by $6.1 million, or 14.5%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The increase in general and administrative expenses was due to a $4.9 million increase in payroll and related costs, including stock compensation expense, and a $3.6 million increase in legal fees primarily driven by ongoing litigation matters, partially offset by a $1.9 million decrease in the provision for allowance for credit losses as compared to the second quarter of 2024 that included a $2.1 million write-off of receivables due from a customer that filed bankruptcy in the second quarter of 2024 and a decrease of $1.3 million in compensation expense related to the milestone obligation for our acquisition of RPM-3D that was incurred in the nine months ended September 30, 2024 but not in the nine months ended September 30, 2025.

*Interest Income.* Interest income decreased $1.7 million, or 43.4%, for the nine months ended September 30, 2025 as compared to the same period in 2024. The decrease in interest income was primarily due to lower balances invested in marketable securities during the current year period.

------

**Liquidity and Capital Resources** 

***Overview***

Before our initial public offering ("IPO"), our primary sources of capital were private placements of common stock and convertible preferred stock, debt financing agreements and revenue from the sale of our products. In April 2021, we received net proceeds of $107.6 million from our IPO. On February 10, 2023, we received net proceeds of $107.5 million from a follow-on public offering of our common stock.

As of September 30, 2025, we had cash and cash equivalents of $7.7 million and marketable securities of $49.7 million available for sale, an accumulated deficit of $239.6 million and $54.0 million of principal outstanding under our term loan and revolving loan agreements. We believe that our existing cash and cash equivalents, marketable securities, available debt borrowings and expected revenues will be sufficient to meet our capital requirements and fund our operations for at least twelve months from the date of issuance of these condensed financial statements. We may be required or decide to raise additional debt or equity financing to support further growth of our operations.

***Funding Requirements*** 

We use our cash, marketable securities, and revenues to fund our operations, which primarily include the costs of manufacturing our products, capital expenditures, as well as our operating expenses. We expect R&D expenses to increase as we continue to hire personnel and invest in next-generation innovations of our existing products and new products. The timing and amount of our operating and capital expenditures and use of available funding will depend on many factors, including:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the scope and timing of our investment in our commercial infrastructure and sales force;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the costs of our ongoing commercialization activities including product sales, marketing, manufacturing, and distribution;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the scope of our marketing efforts, including the degree to which we utilize direct to consumer campaigns;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the degree and rate of market acceptance of our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights, including enforcing our intellectual property rights against infringing products or technologies or enforcing contractual rights against parties breaching agreements with us, including the litigation proceeding we initiated against Stryker and ZB;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the research and development activities we intend to undertake to improve the Lapiplasty System and other products, to commercialize PSI technologies, to gain share in the minimally invasive osteotomy market, and to develop or acquire additional products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the investments we make in acquiring other technologies, assets or businesses to expand our product portfolio;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the success or emergence of new competing technologies or other adverse market developments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•our need to implement additional infrastructure and internal systems;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•competitors' success in inducing surgical facilities to limit their use of our products and surgical facilities' decisions to narrow surgeons' access to our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the effect of inflation, interest rate changes, evolving or increased tariffs, changes in trade policy or global trade disruptions and other general economic conditions on our operations and business;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the ability of customers to pay us for our products, including stocking distributors which generally have longer payment terms than hospital and ambulatory surgery center customers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•any product liability or other lawsuits related to our products;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the expenses needed to attract and retain skilled personnel; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;•the impact of any infectious disease outbreak or natural or other disaster or event beyond our control on our business or on the healthcare industry, particularly elective surgeries where our products are used.

Based upon our current operating plan, we believe that our existing cash, cash equivalents, marketable securities, and available debt borrowings will enable us to fund our operating expenses and capital expenditure requirements for at least the

------

next twelve months. We have based this estimate on assumptions that may prove to be wrong or that may change in the future, and we could utilize our available capital resources sooner than we expect. We may seek to raise any necessary additional capital through public or private equity offerings or debt financings, credit or loan facilities or a combination of one or more of these or other funding sources. Additional funds may not be available to us on acceptable terms or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, we could be forced to delay, limit, reduce or terminate our product development programs, commercialization efforts, sales and marketing initiatives, or other operations. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution, and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to provide additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and in the event of insolvency, debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.

**Cash Flows** 

The following table sets forth the primary sources and uses of cash and cash equivalents for the periods presented below (in thousands):

---

| | | |
|:---|:---|:---|
|  | **Nine Months Ended September 30,** | **Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| Net cash (used in) provided by: |  |  |
| Operating activities | $(7944) | $(32960) |
| Investing activities | 3585 | 31954 |
| Financing activities | 695 | 134 |
| Net increase (decrease) in cash and cash equivalents | $(3664) | $(872) |

---

***Cash Flows from Operating Activities*** 

Net cash used in operating activities for the nine months ended September 30, 2025 was $7.9 million, consisting primarily of a net loss of $49.6 million, adjusted for non-cash charges of $37.1 million and a decrease in net operating assets. The non-cash charges consist primarily of $26.3 million in share-based compensation expense, $7.8 million in depreciation and amortization, $1.7 million in non-cash lease expense, and $0.5 million in provision for allowance for credit losses. The decrease in net operating assets was primarily due to a $7.4 million decrease in accounts receivable from collection on higher sales in the fourth quarter of 2024 and a $5.6 million increase in accounts payable due to timing of payments, partially offset by a $2.4 million decrease in operating lease liabilities, a $3.2 million decrease in accrued liabilities, and a $2.2 million increase in inventory. The decrease in accrued liabilities was primarily from a decrease in accrued commissions from lower sales in the third quarter of 2025 compared to the fourth quarter of 2024, partially offset by increased accrued compensation from timing of payroll and a non-recurring restructuring charge that includes severance and other post-employment benefits.

Net cash used in operating activities for the nine months ended September 30, 2024 was $33.0 million, consisting primarily of a net loss of $55.2 million, adjusted for non-cash charges of $30.6 million and an increase in net operating assets. The non-cash charges consist primarily of $22.0 million in share-based compensation expense, $6.2 million in depreciation and amortization expense, and $2.4 million in provision for allowance for credit losses, primarily due to a significant customer that filed for bankruptcy. The increase in net operating assets was primarily due to a $14.4 million increase in inventories to meet demand for new products and a $12.8 million decrease in accrued liabilities due to timing of payments, and a $0.3 million increase in other non-current assets, partially offset by a $11.5 million decrease in accounts receivable from higher sales in the fourth quarter of 2023, a $6.8 million increase in accounts payable due to timing of payments, and a $0.8 million decrease in prepaid expenses and other current assets.

***Cash Flows from Investing Activities*** 

Net cash provided by investing activities was $3.6 million for the nine months ended September 30, 2025, consisting primarily of $49.6 million in sales and maturities of available-for-sale marketable securities, partially offset by $34.9 million in purchases of available-for-sale marketable securities and $11.1 million in purchases of property and equipment. The net cash generated from marketable securities sales and maturities and purchases of $14.7 million were primarily used to fund our current operations. The purchases in property and equipment included $9.4 million in capitalized surgical instruments for the reusable instrument trays related to our new products, and $1.6 million primarily for equipment, software, and leasehold improvements, to support the growth of our business.

------

Net cash provided by investing activities was $32.0 million for the nine months ended September 30, 2024, consisting primarily of $93.4 million in sales and maturities of available for sale marketable securities, partially offset by $52.9 million in purchases of available for sale marketable securities and $8.5 million in purchases of property and equipment. The net of marketable securities sales and maturities and purchases of $40.5 million were primarily used to fund our current operations. The purchases in property and equipment included $6.7 million in capitalized surgical instruments for the reusable instrument

trays related to new products, and $1.8 million for equipment and leasehold improvements to support the growth of our business.

***Cash Flows from Financing Activities*** 

Net cash provided by financing activities was $0.7 million for the nine months ended September 30, 2025, consisting primarily of $1.6 million in proceeds from insurance premium financing and $0.5 million in proceeds from stock option exercises, partially offset by $0.8 million of shares repurchased for tax withholding on vested RSUs and $0.5 million in payments on insurance premium financing.

Net cash provided by financing activities was $0.1 million for the nine months ended September 30, 2024, consisting primarily of $0.4 million in proceeds from stock option exercises, partially offset by $0.2 million of shares repurchased for tax withholding on vested RSUs.

***Royalty Agreements***

We recognized royalty expense of $1.6 million and $1.4 million for the three months ended September 30, 2025 and 2024, respectively. For the three months ended September 30, 2025 and 2024, the aggregate royalty rate was 3.1% and 3.2%, respectively. We recognized royalty expense of $4.7 million and $4.6 million for the nine months ended September 30, 2025 and 2024, respectively. For the nine months ended September 30, 2025 and 2024, the aggregate royalty rate was 3.1% and 3.3%, respectively. Each of the royalty agreements with our surgeon consultants prohibits the payment of royalties on products sold to entities and/or individuals with whom any of the surgeon consultants is affiliated.

***Operating Lease***

We have commitments for future payments related to our corporate headquarters office located in Ponte Vedra, Florida. We entered into a 10-year lease in February 2022 for our headquarters which expires in July 2032. Lease payments comprise the base rent plus operating costs which include taxes, insurance, and common area maintenance. We also have commitments for future payments related to our former headquarters which expire in April 2026 and have subleased this space for the remainder of our lease term. The remaining lease obligations are $20.8 million under these leases as of September 30, 2025.

**Critical Accounting Policies and Estimates** 

Management's discussion and analysis of our financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of the condensed financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses, and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

***Goodwill***

Our annual impairment testing date was July 1, 2025. We determined after performing the qualitative analysis that there was no evidence that it is more likely than not that the fair value of goodwill was less than the carrying amount. Therefore, it was not necessary to perform a quantitative impairment test. As of September 30, 2025 and December 31, 2024, goodwill was $12.8 million.

Our critical accounting policies and estimates are described in "Management's Discussion and Analysis of Financial Condition and Results of Operations–Critical Accounting Policies and Estimates" in our Annual Report. There were no material changes to these accounting policies during the nine months ended September 30, 2025.

------

**Recently Issued Accounting Pronouncements** 

Refer to Note 3, "Recent Accounting Pronouncements," of the Notes to Condensed Financial Statements for new accounting pronouncements not yet adopted as of this Quarterly Report.

------

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.** 

**Market Risk**

There have been no material changes from the market risk information previously disclosed in our Annual Report under "Part II*–*Item 7A. Quantitative and Qualitative Disclosures About Market Risk."

**Item 4. Controls and Procedures.**

***Evaluation of disclosure controls and procedures***

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

***Changes in internal control over financial reporting***

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

***Inherent limitation on the effectiveness of internal control***

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

------

**PART II–OTHER INFORMATION**

**Item 1. Legal Proceedings.**

Except as described below, we are not a party to any legal proceedings which we believe would have a material adverse effect on our business or results of operations. From time to time, we may become involved in various legal proceedings that arise in the ordinary course of our business.

On April 11, 2025, a shareholder filed a class action complaint in the United States District Court for the Middle District of Florida (captioned *McCluney v. Treace Medical Concepts, Inc. et al.* Case No. 3:25-cv-00390-WWB-PDB) against us and certain of our officers on behalf of all persons who purchased or otherwise acquired our stock between May 8, 2023 and May 7, 2024 alleging that we and certain of our current executives violated the federal securities laws by making false or misleading statements and failing to disclose material adverse facts about our business, operations and prospects. Specifically, the complaint alleges that we failed to disclose the impact of competition on demand for and utilization of our products and the need to accelerate our plans to offer a new osteotomy product and that our positive statements about our business, operations, and prospects were materially misleading and/or lacked a reasonable basis. The plaintiffs seek unspecified monetary damages, costs, and attorneys' fees. On July 1, 2025, the court appointed the lead plaintiff and lead counsel. The plaintiffs filed an amended complaint on July 31, 2025, and we filed a motion to dismiss on September 5, 2025. The action is in the preliminary stage. We dispute the allegations in the complaint and intend to defend against this complaint vigorously. Based on the preliminary nature of the proceedings in this action, the outcome remains uncertain, and we cannot reasonably estimate the potential impact, if any, on our business or financial statements at this time. We are insured for Directors and Officers liability for amounts in excess of the retention and up to the policy limits.

On October 14, 2024, we filed a lawsuit against Stryker Corporation and its subsidiary Wright Medical Technology, Inc. alleging infringement of 9 patents related to our innovative Lapiplasty 3D Bunion Correction technologies and unfair competition. The suit was filed in the United States District Court for the District of New Jersey and seeks injunctive relief and damages. On January 24, 2025, Stryker filed a motion to dismiss the unfair competition claims which the Court granted on October 2, 2025 without prejudice. The Company filed a first amended complaint on October 24, 2025.

On May 23, 2025, Stryker European Operations Holdings LLC and Howmedica Osteonics Corp. filed a suit against us for patent infringement by our hammertoe product. The plaintiffs seek findings of patent infringement, equitable relief, unspecified monetary damages, enhanced damages for willful patent infringement, interest, costs, and attorneys' fees. We dispute the allegations in the complaint, and on August 4, 2025, we moved to dismiss all of the claims in the suit. Based on the preliminary nature of the proceedings in this action, the outcome remains uncertain, and we cannot estimate the potential impact, if any, on our business or financial statements at this time.

On May 12, 2025, we filed a lawsuit against Zimmer Biomet Holdings, Inc. and Paragon 28, Inc. alleging infringement of 4 patents related to our innovative Lapiplasty 3D Bunion Correction technologies. The suit was filed in the United States District Court for the District of Delaware and seeks injunctive relief and damages. On August 5, 2025, we filed an amended complaint alleging infringement of an additional patent.

On August 29, 2025, Paragon 28, Inc. and Disior Oy filed a lawsuit against us and RPM-3D alleging RPM-3D improperly acquired, used, and disclosed confidential and trade secret technology from Disior's software to develop software acquired by us. The suit was filed in the United States District Court for the District of Delaware and seeks injunctive relief and damages. The deadline for us to move, answer or otherwise respond to the Complaint is December 10, 2025.

**Item 1A. Risk Factors.**

There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K under "Part I, Item 1A*–*Risk Factors" for the year ended December 31, 2024, filed with the SEC on February 27, 2025.

------

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

*Issuer Purchases of Equity Securities*

The following table presents information with respect to the Company's repurchases of stock during the three months ended September 30, 2025.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Period** | **Total Number of Shares Purchased** | **Average Price Paid Per Share** | **Total Number of Shares Purchased as part of Publicly Announced Plans or Programs** | **Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs** |
| July 1 to July 31, 2025 |  | $— |  |  |
| August 1 to August 31, 2025<sup>(1)(2)</sup> | 47448 | 6.39 |  |  |
| September 1 to September 30, 2025<sup>(1)(2)</sup> | 16234 | 6.71 |  |  |
| Totals | 63682 | $6.47 |  |  |

---

(1)Includes restricted shares withheld pursuant to the terms of awards under the Company's share-based compensation plans to offset tax withholding obligations that occur upon vesting and release of restricted shares.

(2)The value of the restricted shares withheld is the closing price of the Company's common stock on the date the relevant transaction occurs.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

Not applicable.

**Item 5. Other Information.**

None.

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | **Description** |
| 31.1 | [<u>Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](tmci-ex31_1.htm) |
| 31.2 | [<u>Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</u>](tmci-ex31_2.htm) |
| 32.1† | [<u>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](tmci-ex32_1.htm) |
| 32.2† | [<u>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</u>](tmci-ex32_2.htm) |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

† The certifications attached as Exhibit 32.1 and 32.2 to this Quarterly Report are deemed furnished and not filed with the U.S. Securities and Exchange Commission and are not to be incorporated by reference into any filing of Treace Medical Concepts, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report, irrespective of any general incorporation language contained in such filing.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Treace Medical Concepts, Inc.** | **Treace Medical Concepts, Inc.** | **Treace Medical Concepts, Inc.** |
| Date: November 6, 2025 | By: | /s/ John T. Treace | /s/ John T. Treace |
|  |  | Name: | John T. Treace |
|  |  | Title: | Chief Executive Officer (Principal Executive Officer) |
| Date: November 6, 2025 | By: | /s/ Mark L. Hair | /s/ Mark L. Hair |
|  |  | Name: | Mark L. Hair |
|  |  | Title: | Chief Financial Officer (Principal Financial Officer) |

---

------

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, John T. Treace, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Treace Medical Concepts, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 6, 2025 | By: | /s/ John T. Treace |
|  |  | John T. Treace |
|  |  | Chief Executive Officer (Principal Executive Officer) |

---

------

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION PURSUANT TO**

**RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002**

I, Mark L. Hair, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Treace Medical Concepts, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: November 6, 2025 | By: | /s/ Mark L. Hair |
|  |  | Mark L. Hair |
|  |  | Chief Financial Officer<br>(Principal Financial Officer) |

---

------

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Treace Medical Concepts, Inc. (the "Company") for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 6, 2025 | By: | /s/ John T. Treace  |
|  |  | John T. Treace  |
|  |  | Chief Executive Officer <br>(Principal Executive Officer) |

---

------

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Treace Medical Concepts, Inc. (the "Company") for the quarter ended September 30, 2025 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: November 6, 2025 | By: | /s/ Mark L. Hair |
|  |  | Mark L. Hair |
|  |  | Chief Financial Officer<br>(Principal Financial Officer) |

---

------